Table 2.
Association of the preoperative plasma uPAR forms with clinical and pathological characteristics.
| Characteristics | uPAR (I−III) | uPAR (I−III) + uPAR (II−III) | uPAR (I) | |||
|---|---|---|---|---|---|---|
| pmol/L | pmol/L | pmol/L | ||||
| Median (Min-Max) | p-Value | Median (Min-Max) | p-Value | Median (Min-Max) | p-Value | |
| Age | ||||||
| 67 (44–81) a | 0.15 | 0.13 | 0.13 | 0.17 | −0.03 | 0.78 |
| Gender | ||||||
| Female | 53.65 (31.98–91.43) | 94.73 (68.90–226.21) | 38.85 (17.04–754.88) | |||
| Male | 42.69 (19.34–76.66) | 0.003 | 84.68 (51.60–156.67) | 0.02 | 35.60 (16.40–124.15) | 0.05 |
| Pathologic stage (cystectomy specimen) b | ||||||
| pT ≤ pT2 pN0 | 42.72 (19.34–76.66) | 85.14 (51.60–156.67) | 34.09 (16.40–124.15) | |||
| pT ≥ pT3 pN0 | 53.28 (31.44–68.37) | 0.15 | 101.25 (73.52–145.19) | 0.03 | 42.99 (17.04–86.66) | 0.06 |
| pTany pN+ | 42.25 (27.47–91.43) | 84.99 (55.20–226.21) | 34.00 (21.08–754.88) | |||
| Pathologic grade | ||||||
| LG | 54.96 (45.91–64.00) | 107.33 (79.36–135.29) | 58.14 (57.62–58.65) | |||
| HG | 44.50 (25.62–91.43) | 0.59 | 87.51 (51.60–226.21) | 0.71 | 36.45 (16.40–754.88) | 0.38 |
| Concomitant CIS | ||||||
| No | 42.71 (19.34–91.43) | 88.19 (53.07–226.21) | 35.91 (19.38–754.88) | |||
| Yes | 48.09 (26.49–76.66) | 0.39 | 89.56 (51.60–132.43) | 0.96 | 38.89 (16.40–142.10) | 0.44 |
| Lymph vascular invasion | ||||||
| No | 44.05 (19.34–91.43) | 88.19 (51.60–156.67) | 35.91 (16.40–754.88) | |||
| Yes | 46.06 (32.02–78.11) | 0.53 | 89.15 (57.15–226.21) | 0.31 | 39.60 (24.68–142.10) | 0.20 |
| Resection margin | ||||||
| Negative | 43.23 (19.34–91.43) | 87.51 (51.60–156.67) | 35.91 (16.40–754.88) | |||
| Positive | 51.12 (44.41–78.11) | 0.09 | 128.56 (77.47–226.21) | 0.05 | 46.75 (25.00–107.60) | 0.27 |
| Lymph node metastasis | ||||||
| No | 44.41 (19.34–76.66) | 89.35 (51.60–156.67) | 36.45 (16.40–124.15) | |||
| Yes | 42.25 (27.47–91.43) | 0.92 | 84.99 (55.20–226.21) | 0.87 | 34.00 (21.08–754.88) | 0.05 |
| Neoadjuvant chemotherapy | ||||||
| No | 44.41(/19.34–78.11) | 87.51 (5160–228.21) | 35.60 (16.40–142.10) | |||
| Yes | 43.55 (25.62–91.43) | 0.85 | 89.42 (57.04–156.67) | 0.97 | 37.61 (19.38–754.88) | 0.17 |
Descriptive statistics presented with median, minimum and maximum concentrations for the different uPAR forms (pmol/L). a Spearman’s rank correlation coefficient (rs), p-value testing the hypothesis that rs = 0. b p-values are for the Wilcoxon rank sum test comparing the levels of the uPAR concentrations for baseline patients characteristic. CIS = carcinoma in situ; LG = low grade; HG = high grade.